Atossa Genetics, Inc. to Present at the Personalized Medicine World Conference in Mountain View, California

SEATTLE, WA--(Marketwire - Jan 17, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President of Atossa, will make two presentations at the Personalized Medicine World Conference (PWMC) being held at the Computer History Museum in Mountain View, California, on January 28^th and 29^th, 2013. Dr. Quay will discuss a strategy for providing care to patients at every stage of a disease or condition, and how it may be possible to actually prevent breast cancer.

Here are summaries of his two presentations:

The "CarePath" Business Model in Personalized Medicine - 9:45 am Pacific Time, Jan. 28, 2013

Abstract: Medical practice is moving toward treatments that are based on simple protocols. For example, if a woman has a lump in her breast, she typically gets a standard biopsy. These so-called protocol-driven treatment paradigms thus make it hard for genomics-based diagnostic companies to launch innovative tests that may offer better care but which don't fit the established protocol. There is another possible approach, however -- designing a suite of tests and procedures that work together to help patients at every stage of a disease or condition. Atossa Genetics calls this the 'CarePath' business model, and believes it offers an insightful way to distinguish a truly innovative company from the crowd, to better treat a medical condition by establishing synergies across all parts of the business, and to build stakeholder value for the organization. Atossa Genetics has created such a CarePath for breast health with eleven FDA-cleared medical devices, four CLIA-validated Laboratory Developed Tests, and a planned pharmaceutical/biotech treatment program.

Breast Cancer Prevention through Diagnosis and Treatment - 4:15 pm Pacific Time, Jan. 28, 2013

Abstract: Dr. Quay will discuss how to obtain routine, repeated, painless breast biopsy samples non-invasively for cytopathology, next-generation sequencing, proteome, and transcriptome analysis of precursors to breast cancer. This approach makes it possible to identify the earliest "-omic" changes in reversible precursor lesions of the breast, such as atypical ductal hyperplasia. The test not only provides more accurate assessments of patients' risks of future breast cancer, it also offers a source of breast specimens for potential use in biomarker discovery, clinical trial support and patient selection. And most importantly, it opens the door to ultimately preventing breast cancer through the treatment of reversible hyperplastic lesions within the breast ducts.

"Our personalized medicine approach to breast health represents a new paradigm in the way we think about and approach breast cancer and breast cancer prevention," stated Dr. Quay. "I appreciate the opportunity to make two presentations at this important conference, which brings together thought leaders from many prestigious institutions, including Stanford University, Harvard University and other world-renowned institutions."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission and other reports filed with the SEC. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.